Videos

Pediatric experts link insomnia and mental health, favor CBT over sedatives, and warn against cannabis for sleep.

Explore how circadian gene rhythms differ in schizophrenia, depression, and bipolar disorder—and why stable sleep timing may curb addiction risk.

Sleep and circadian rhythm disruption shape psychiatric symptoms and bipolar mood shifts.

MAPS probes psychedelic-assisted healing for formerly incarcerated people, spotlighting trauma, access barriers, and a public-health policy path.

Alkermes’ phase 2 Vibrance-2 shows alixorexton significantly boosts wakefulness and reduces daytime sleepiness in narcolepsy type 2, with benefits sustained.

New SLEEP 2026 data show orexin agonist oveporexton boosts cognition, daily function, and reduces microsleeps in narcolepsy type 1.

Check out new phase 2 dose-ranging study data evaluating alixorexton in patients with narcolepsy type 2.

REFRESH data show once-nightly sodium oxybate real-world outcomes.

REFRESH real-world study follows once-nightly sodium oxybate in narcolepsy.

Long-term study links sleep problems to poorer well-being in aging adults, highlighting sex differences and why insomnia isn’t just aging.

New phase 3 data show oveporexton (TAK-861) boosts functioning and cognition, eases NT1 symptoms, and improves sleep

New spectral sleep analysis and HD‑tDCS aim to strengthen restorative sleep and memory, offering promise for schizophrenia-related cognitive deficits.

Welcome back to another Psychiatric Times Insights series. In this episode titled, "The Switch Study: Why a New Mechanism Demands a New Approach," David Walling, PhD, address the unmet clinical needs in schizophrenia treatment that motivated the development of the study evaluating the transition from atypical antipsychotics to Cobenfy?

New SLEEP 2026 insights reveal how REM sleep preserves memories while stripping emotional sting—key clues for PTSD and healthier sleep.

Behavioral therapies: important parts of sleep disorder treatment.

Menopause-related sleep disruptions and slow-wave scoring bias may skew women’s neurodegeneration risk insights, SLEEP 2026 highlights.

Clinicians weigh diagnosis clarity, side effects, and adherence when choosing antipsychotic formulations, often starting oral therapy then switching to long-acting injectables.

Explore today’s schizophrenia treatments, comparing first-, second-, and newer antipsychotics, clozapine’s role, and how side effects and adherence drive medication choices.

Explore how digital reminders boost prospective memory in aging and dementia, plus practical sleep habits that turn health knowledge into real behavior changes.

Learn more about the bidirectional relationship between sleep and waking behaviors.

Learn why awakenings are normal, sleep needs shift with age, and deep sleep protects brain health and cognition.

New research links sleep inertia and daytime sleepiness to dangerous falls in older adults—learn which sleep habits may prevent injuries.

Learn more about sleep issues and their relation to Alzheimer disease.

New research links better NREM sleep to slower Alzheimer disease changes: zolpidem restores brain rhythms, cuts amyloid, and boosts memory in mice models.

Explore the intersections of bipolar disorder with clinical trials and AI.

Caplyta boosts antidepressants in MDD, showing 2–4 week response with minimal weight, metabolic, and EPS risks.

Carlos H. Schenck, MD, delivered the keynote address at SLEEP 2026 on REM sleep behavior disorder. Here's what psychiatrists and mental health clinicians need to know.

Delphi panel reveals how NPs and PAs can talk about long-acting injectables earlier in schizophrenia, boosting adherence and cutting relapse.

Let's take a look at the next generation of pharmacotherapies for mood and anxiety disorders.

Alixorexton boosts wakefulness in type 1 narcolepsy, shows cognitive and fatigue gains, and hints at ADHD and neurodegenerative uses.